AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Type
Public
HQ
Cambridge, GB
Founded
1999
Size (employees)
61,100 (est)+3%
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Report incorrect company information

Key People/Management at AstraZeneca

Leif Johansson

Leif Johansson

Non-Executive Chairman of the Board
Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Rudy Markham

Rudy Markham

Senior Independent Non-Executive Director
Genevieve Berger

Genevieve Berger

Non-Executive Director
Philip Broadley

Philip Broadley

Non-Executive Director
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Wilmington, Colorado Springs, London, Cambridge and in 166 other locations
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Wedel, DE
Wedel, Tinsdaler Weg 183
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
London, GB
15 Stanhope Gate
Show all (171)
Report incorrect company information

AstraZeneca Financials and Metrics

AstraZeneca Revenue

Embed Graph
AstraZeneca's revenue was reported to be £22.46 b in FY, 2017
GBP

Revenue (FY, 2017)

22.5 b

Gross profit (FY, 2017)

18.1 b

Gross profit margin (FY, 2017), %

80.8%

Net income (FY, 2017)

2.9 b

EBITDA (FY, 2017)

6.7 b

EBIT (FY, 2017)

3.7 b

Market capitalization (16-Aug-2018)

96.2 b

Closing stock price (16-Aug-2018)

38

Cash (31-Dec-2017)

3.3 b

EV

95.1 b
AstraZeneca's current market capitalization is $96.2 b.
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.4 b5.2 b5.5 b11.4 b12.1 b11.4 b11.1 b10.5 b11.5 b14 b13.5 b14.8 b19.8 b16.9 b19.6 b19.1 b23 b22.5 b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

2.2 b2 b2.2 b3.7 b3.7 b3.1 b2.8 b2.5 b2.8 b3.1 b2.7 b3.2 b4.1 b3.5 b4.3 b3.6 b4.1 b4.3 b

Gross profit

3.1 b3.2 b3.4 b7.6 b8.4 b8.3 b8.3 b8 b8.7 b10.8 b10.8 b11.6 b15.7 b13.4 b15.3 b15.5 b18.9 b18.1 b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

259 m303 m206 m265 m683 m489 m453 m409 m565 m2.9 b3.6 b2.9 b2.7 b6.1 b4.7 b4.8 b5 b3.3 b

Accounts Receivable

935 m969 m1.1 b1.8 b1.8 b1.7 b1.7 b1.8 b1.9 b2.2 b2.2 b2.7 b3.5 b3.6 b3.5 b3.6 b2.6 b2.8 b

Inventories

681 m728 m798 m1.3 b1.4 b1.7 b1.6 b1.7 b1.6 b1.3 b1.2 b1.1 b1 b1.3 b1.4 b1.7 b2.3 b3 b

Current Assets

3 b2.9 b2.7 b6.1 b7 b6.8 b7.6 b7.2 b7.7 b8 b8.7 b8.6 b10 b13.2 b12.2 b12.3 b13 b12.9 b
GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

655 m736 m715 m704 m1.7 b2.1 b1.8 b1.7 b2.1 b2.8 b3.1 b2.8 b3.8 b1.7 b913.3 m2.2 b3.4 b2.9 b

Cash From Operating Activities

1.1 b1.2 b1.2 b1.9 b2.8 b2.6 b3.5 b2.4 b3.2 b3.9 b3.9 b3.8 b5.5 b4.9 b5.2 b4 b4.1 b3.6 b

Dividends Paid

332 m365 m399 m764 m1.9 b850 m753 m754 m833 m976 m1.1 b1.3 b1.7 b2.6 b2.7 b

Cash From Financing Activities

(39 m)(32 m)(96 m)(112 m)(267 m)(665 m)(794 m)(811 m)(740 m)(2.7 b)(2.7 b)3 b(4 b)(2 b)(2 b)3.4 b(1.3 b)(2.9 b)
GBPY, 2017

EV/EBITDA

14.2 x

EV/EBIT

25.9 x

EV/CFO

26.6 x

Revenue/Employee

367.7 k

Debt/Equity

0.2 x

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Health Facilities Activated

250 403

Phase I Trials Products

33 24 44 41

Projects in R&D Pipeline

99 133 146 132

Young Health Programme Members

1.40 m1.60 m
Show all operating metrics

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

Report incorrect company information

AstraZeneca Online and Social Media Presence

Embed Graph
Report incorrect company information

AstraZeneca News and Updates

D-Amino Acids Global Market 2018: Key Players – Ajinomoto Co., Inc., Akorn, Inc., Alcon, Inc., AstraZeneca plc, Arun & Co.

D-Amino Acids -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021 Posted via Industry Today. Follow us on Twitter @IndustryToday

AstraZeneca Pharma shares zoom nearly 11 pc

Shares of AstraZeneca Pharma India today surged nearly 11 per cent after the company received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer. The stock soared 7.63 per cent to end at Rs 1,840.75 on…

AstraZeneca Pharma gains after securing permission

AstraZeneca Pharma India rose 3.04% to Rs 1,762.30 at 10:45 IST on BSE after the company announced receiving marketing permission for Olaparib tablet.

AstraZeneca Pharma India gets DCGI nod to market cancer drug in India

Drug firm AstraZeneca Pharma India today said it has received permission from the Drug Controller General of India (DCGI) to import and market olaparib tablets used for the treatment of ovarian and breast cancer. The permission from the DCGI is for olaparib (Lynparza) tablets in the strengths of 100…

AstraZeneca Pharma India Q1 net profit up 10% at Rs 6.39 cr

Drug firm AstraZeneca Pharma India today reported a 10.36 per cent rise in its net profit to Rs 6.39 crore for the quarter ended June 30. The company had posted a net profit of Rs 5.79 crore for the corresponding period previous fiscal, AstraZeneca Pharma India said in a BSE filing. The company's re…

London Markets: FTSE 100 closes lower as TUI sinks, offsets Fresnillo’s gain

The U.K.’s main stock benchmark finishes the session lower on Thursday, ending a four-day winning streak for the FTSE 100, as a gain in health-related companies AstraZeneca PLC and metals producer Fresnillo PLC are more than offset by a plunge in shares of TUI AG.
Show more
Report incorrect company information

AstraZeneca Company Life and Culture

Report incorrect company information